PLx Pharma Inc. PLXP
Set alert
At close · Apr 12
52-week range unavailable
- Open
- 0.0953
- Prev close
- 0.087
- Mkt cap
- 2.53M
- Vol
- 50.38M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0826
- High
- 0.1555
- Forward P/E
- -0.08
- Beta
- 3.92
- Short ratio
- 0.83
- Inst. own
- 23.25%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 12, 2023
- 50-d avg
- 0.136178
- 200-d avg
- 0.558388
- 1y target
- 0.00
Key statistics
- Market cap
- 2.53M
- Enterprise value
- -8.92M
- Trailing P/E
- 0.00
- Forward P/E
- -0.08
- PEG ratio
- 0.00
- Price / sales
- 0.56
- Price / book
- 0.25
- EPS (TTM)
- -0.39
- Beta
- 3.92
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 4.54M
- Revenue growth
- -94.20%
- Free cash flow
- -35.21M
- Total cash
- 25.83M
- Total debt
- 171.68K
- Return on equity
- -75.18%
- Shares outstanding
- 29.14M
- Short % of float
- 0.86%
- 50-day average
- 0.136178
- 200-day average
- 0.558388
Analyst view
Consensus: hold
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
May 12, 2023
Expected May 12, 2023. Consensus EPS estimate -0.28.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 12, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
| Nov 10, 2022 | Sep 1, 2022 | -0.44 | — | — | — |
| Aug 12, 2022 | Jun 1, 2022 | -0.56 | — | — | — |
| May 13, 2022 | Mar 1, 2022 | -0.69 | — | — | — |
| Mar 11, 2022 | Dec 1, 2021 | -0.69 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 15, 2022 | JMP Securities | down | Market Outperform | Market Perform |
| Aug 15, 2022 | Oppenheimer | down | Outperform | Perform |
| May 16, 2022 | Raymond James | main | — | Outperform |
| Mar 14, 2022 | Raymond James | main | — | Outperform |
| Dec 7, 2021 | Raymond James | up | Market Perform | Outperform |
| Sep 21, 2021 | BWS Financial | init | — | Buy |
About PLx Pharma Inc.
PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever. The company sells its products through drugstores, mass merchandisers, grocery stores, and e-commerce channels. PLx Pharma Inc. was incorporated in 2002 and is headquartered in Sparta, New Jersey. On April 13, 2023, PLx Pharma Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
- Country
- United States
- Website
- plxpharma.com
News
- Why Is PLx Pharma (PLXP) Stock Down 32% Today?
- Why Is PLx Pharma (PLXP) Stock Down 38% Today?
- Spotting Winning Penny Stocks: 3 Top Tips
- Why Tupperware Brands Shares Are Trading Lower By Over 40%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- Stocks That Hit 52-Week Lows On Tuesday
- Stocks That Hit 52-Week Lows On Wednesday
- Stocks That Hit 52-Week Lows On Friday
- Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday
- PLx Pharma (PLXP) Q3 2022 Earnings Call Transcript
Your note
Sign in to keep a note on PLXP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BALKEMA GARY S | Director | Stock Award(Grant) | Apr 18, 2017 | 5,445 |
| CALHOUN KIRK K | Director | Stock Award(Grant) | Apr 18, 2017 | 1,675 |
| CASALE ROBERT DANIEL | Director | Stock Award(Grant) | Apr 18, 2017 | 2,710 |
| GIORDANO NATASHA | Chief Executive Officer | Purchase | Mar 14, 2022 | 5,186 |
| HADDEN JOHN W. II | Director | Purchase | Dec 13, 2020 | 3,690 |
| JORDEN DAVID EMERSON | Chief Financial Officer | Purchase | Jun 13, 2017 | 151,913 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Park West Asset Management LLC | 5.06% | 1,473,218 | 128.17K | Dec 30, 2022 |
| Green Square Capital, LLC | 3.39% | 987,000 | 85.87K | Dec 30, 2022 |
| Blackrock Inc. | 1.42% | 413,520 | 35.98K | Dec 30, 2022 |
| Vanguard Group, Inc. (The) | 1.16% | 338,522 | 29.45K | Dec 30, 2022 |
| Geode Capital Management, LLC | 0.82% | 237,491 | 20.66K | Dec 30, 2022 |
| Ground Swell Capital, LLC | 0.75% | 218,820 | 19.04K | Dec 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.55% | 743,824 | 64.71K | Sep 29, 2022 |
| Vanguard Extended Market Index Fund | 1.13% | 329,367 | 28.65K | Sep 29, 2022 |
| Fidelity Extended Market Index Fund | 0.46% | 134,443 | 11.70K | Nov 29, 2022 |
| iShares Micro Cap ETF | 0.18% | 53,451 | 4.65K | Dec 30, 2022 |
| Fidelity Total Market Index Fund | 0.12% | 35,408 | 3.08K | Nov 29, 2022 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.11% | 30,686 | 2.67K | Dec 30, 2022 |